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ABSTRACT 
A series of multi-target directed propargylamines, as well as other differently susbstituted 
piperidines have been screened as potential modulators of neuronal nicotinic acetylcholine 
receptors (nAChRs). Most of them showed antagonist actions on α7 nAChRs. Especially, 
compounds 13, 26 and 38 displayed sub-micromolar IC50 values on homomeric α7 nAChRs 
whereas they were less effective on heteromeric α3β4 and α4β2 nAChRs (up to 20-fold 
higher IC50 values in the case of 13). Antagonism was concentration dependent and non-
competitive, suggesting that these compounds behave as negative allosteric modulators of 
nAChRs. Upon the study of a series of less complex derivatives, the N-benzylpiperidine 
motif, common to these compounds, was found to be the main pharmacophoric group. Thus, 
2-(1-benzylpiperidin-4-yl)-ethylamine (48) showed an inhibitory potency comparable to the 
one of the previous compounds and also a clear preference for α7 nAChRs. In a 
neuroblastoma cell line, representative compounds 13 and 48 also inhibited, in a 
concentration-dependent manner, cytosolic Ca
2+
 signals mediated mainly by α7 nAChRs. 
Finally, these compounds, especially 38 and 13, inhibited 5-HT3A serotonin receptors 
whereas they had no effect on α1 glycine receptors. 
KEYWORDS: Nicotinic receptors, Piperidine derivatives, α7, Ionic currents, blockers. 
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INTRODUCTION 
Neuronal nicotinic acetylcholine receptors (nAChRs) are ion channels that modulate fast 
synaptic transmission in nerve cells and are widely found in both the peripheral and central 
nervous systems. They are composed of five subunits assembled around the ion pore. Twelve 
subunits (α2-α10 and β2-β4) have been identified and cloned. Heteromeric or homomeric 
assembly of subunits result in the expression of functional nAChRs whose pharmacological 
and electrophysiological properties depend on their subunit composition
1
. Homomeric α7 
nAChRs have received much attention, given their characteristic features, different of other 
neuronal nAChRs, such as rapid channel activation and inactivation and high Ca
2+
 
permeability.
2
  The latter property suggests the involvement of α7 nAChRs in processes 
beyond their channel activity.
3
 Since α7 nAChRs appear to play an important role in central 
and peripheral diseases that involve, among others, cognition disorders,
4-6
 schizophrenia,
7
 
pain
8
 and inflammation,
9
 considerable effort has been dedicated to develop therapeutic agents 
that target this receptor subtype.
10
 
In the last years, some of us have reported a number of multi-target directed 
propargylamines (MTDP) able to bind simultaneously the cholinesterase and monoamine 
oxidase enzymes as a promising therapeutic strategy for the development of new drugs for 
Alzheimer’s disease (AD).
11
 Particularly attractive has resulted MTDP ASS234, a hybrid 
molecule resulting from the juxtaposition of donepezil (DNP) (Aricept
®
), a cholinesterase 
inhibitor currently prescribed for AD patients, and MTDP PF9601N (1) (Figure 1), a potent 
and selective MAO B inhibitor previously developed in our laboratory.
12, 13
 At present, 
ASS234 is our most advanced lead-compound for the potential treatment of AD.
14-16
 
Based on these precedents, and in order to potentiate the polyphamarcology of hybrid 
ASS234 for AD, we focused on its potential ability to modulate nAChRs. In fact, the capacity 
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of diversely substituted piperidines to act as α7 nAChR antagonists
17
 and the presence of the 
N-benzylpiperidine motif in compound ASS234, set up the rational basis to start this project. 
As a result, we have explored a number of MTDPs from our stock library and current 
research projects, as well as other differently susbstituted piperidines as potential modulators 
of nAChRs. This effort enabled us to identify several hybrid molecules able to strongly 
inhibit α7 nAChRs, as well as detect the N-benzylpiperidine structural motif, present in 
almost all the compounds studied, as the main pharmacophoric group responsible for the 
inhibitory activity.   
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RESULTS AND DISCUSSION 
Propargylamine ASS234 inhibits α7 nAChRs. Compound ASS234 was evaluated 
as modulator of α7 nAChRs expressed in Xenopus oocytes. For this purpose, different 
concentrations of ASS234 were co-applied with acetylcholine (ACh) (200 µM), and the 
resulting currents were compared to those induced by ACh alone (Figure 2A). In the presence 
of ASS234 a substantial decrease was observed in the ionic currents. Their decay, however, 
was similar to control currents, so that changes in kinetics were not apparent (Figure 2A). 
The inhibitory effect of ASS234 is dose dependent. Figure 2B shows concentration-response 
relationships of the effect of ASS234 on peak currents of α7 nAChRs.  IC50 value was close 
to 2 µM. Concentration-response relationships of ACh for α7 nAChRs (Figure 2C) were 
generated. In all cases there is a reduction of Imax (of about 70%) in the presence of ASS234 
suggesting a noncompetitive mechanism of action of this compound on α7 nAChRs. 
Furthermore, we observed a slight right shift of the apparent EC50 that increased by a factor 
of about 2.  Finally, compound ASS234 was also evaluated for its activity at α4β2 and α3β4 
nAChRs expressed in Xenopus oocytes, as these two receptor subtypes constitute typical 
representatives of central and peripheral heteromeric receptors, respectively. While ASS234 
was able to inhibit the currents induced by ACh at these receptor subtypes, the effect was less 
prominent than in α7 receptors (Figure 2D). Thus, in the presence of 10 µM ASS234, 30.5 
and 48% of the ACh-evoked current was inhibited in α3β4 and α4β2 nAChRs, respectively, 
whereas in α7 nAChRs, a current inhibition of 94.5% was observed. Therefore, ASS234 is 
highly although not totally selective towards α7 nAChRs. 
Screening of a library of structurally related compounds. Given the results 
obtained with ASS234 we decided to explore a library of structurally related compounds 1-41 
(Figures 1, 4 and 1S-8S, see Supporting Information) that had been designed, synthesized 
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and biologically evaluated in the context of our current program  targeted to  discover  new  
molecules for  AD.
12, 18-22
 
As in the case of ASS234, each compound was individually tested by co-application 
with ACh to α7 nAChRs. As shown in Figure 3, a varied degree of inhibitory responses of 
ACh-induced currents was observed, whereas no significant potentiation was exerted by any 
of the tested compounds. A more detailed comparison of the most potent inhibitors and DNP, 
as a reference (see Figure 4 for chemical structures), is shown in Table 1. At 1 µM the most 
effective inhibitors were compounds 13, 26 and 38, whereas related compounds 11, 22, 37 
and 39 induced weaker responses, and DNP did not affect the current. By contrast, at 10 µM 
all compounds, with the exception of DNP, were equally effective, inhibiting the ACh-
induced current almost totally. DNP only inhibited half of the current at this concentration 
(Table 1).  
 
Table 1. Effect of two different concentrations of DNP and the most potent inhibitors on 
ACh-evoked currents in α7 nAChRs.
a
 
 
Compound 
Normalized current 
1 µM 10 µM 
DNP 97±6.6 50.3±2.8 
11 57.3±9.4 3±3 
13 16.3±2.8 1.5±0.5 
22 70±6.4 1 
26 29.7±5.8 1 
37 73±0.6 2.7±0.3 
38 30.3±2.2 0 
39 48.3±0.9 0.7±0.3 
 
a
Mean (± S.E.) currents of α7 nAChRs elicited by 200 µM ACh in the presence of the 
indicated concentrations of the different compounds. The currents are normalized to control 
values (100%) observed with only ACh. 
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Figure 5 features a more comprehensive study of DNP and the most potent inhibitors 
(13, 26 and 38). Concentration-response relationships (Figure 5A) showed that compound 13 
was almost 2-fold more potent than compounds 26 and 38 and about 30-fold more potent 
than DNP in blocking α7 nAChRs responses elicited by 200 µM ACh. Concentration-
response relationships for ACh were slightly displaced to the right in the presence of all 
compounds (Figure 5B). Thus, EC50 for ACh was 202 µM in control conditions and 360, 424, 
563 and 676 µM  in the presence of compounds 38, 13, DNP, and 26, respectively. Although 
these data do not rule out totally a competitive mechanism, they strongly suggest that these 
compounds behave as negative allosteric modulators of the α7 nAChRs.  
Compounds 13, 26, 38 and DNP were also evaluated for its activity at α3β4 and α4β2 
nAChRs (Figure 6A). The inhibiting action was less prominent in all cases, especially on 
α4β2 nAChRs. Thus, in the presence of 10 µM 13, only 59% of the ACh-evoked current was 
inhibited in α3β4 and α4β2 nAChRs. DNP and 26 were even less effective in their inhibition 
(about 36-12%) whereas 38 showed more inhibition of α3β4 (66%) than of α4β2 currents 
(42%).  At this concentration compounds 13, 26 and 38 inhibited totally α7 currents (Table 1) 
In order to compare IC50 values in the three receptor subtypes, we determined concentration-
response relationships of 13 for α3β4 and α4β2 nAChRs (Figure 6B). Thus, the IC50 values 
for α3β4 and α4β2 nAChRs were 7.2 and 6 µM, respectively, about 20-fold higher than in the 
case of α7 nAChRs. Therefore, and as previously observed with ASS234, the compounds are 
clearly more potent on α7 nAChRs. 
Derivatives of N-benzylpiperidine act as inhibitors of α7 nAChRs. Despite their 
structural heterogeneity, all compounds from the previous screening that showed significant 
inhibitory activity, had in common the N-benzylpiperidine motif. Therefore, it would be of 
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interest to clear the role of this functional and structural motif as potential pharmacophoric 
group responsible for the observed biological activity.  
For this purpose, we explored the activity of less bulky N-benzylpiperidine 
derivatives, such as chlorides 42,
23 
43,
24 
alcohols 44,
25 
45,
26
 and amines 46,
25
 47,
27
 48,
28
 49,
29
 
and 50
30
 (Figure 7) on α7 nAChRs. The effect of 1 and 10 µM N-benzylpiperidines on the 
magnitude of α7 nAChR peak currents elicited by ACh is shown in Figure 8. The most 
effective N-benzylpiperidines were amines 47-50, which exhibited almost complete inhibition 
of α7 currents at 10 µM. These compounds were selected for a more detailed study of 
concentration-response relationships (Figure 9). Compound 48 was the most potent inhibitor 
(IC50 0.58 µM), with compounds 49 and 50 having intermediate potencies (IC50 1.4 and 1 
µM, respectively) and compound 47 being the less potent (IC50 2.2 µM). Therefore, a 
separation of two carbon atoms between the piperidine and the amino group seems optimal 
for the antagonist activity of these derivatives. Concentration-response relationships for ACh 
were slightly displaced to the right in the presence of all compounds (Figure 9B). Thus, EC50 
for ACh was 207 µM in control conditions and 458, 312, 369 and 277 µM  in the presence of 
compounds 47, 48, 49, and 50, respectively, suggesting that these compounds also behave as 
negative allosteric modulators of the α7 nAChRs. The inhibitory potency of compound 48 is 
comparable to the one of compounds 26 and 38, and only two-fold lower that of compound 
13.. In addition, and as it was observed with the latter compounds, 48 was less effective on 
α3β4 and α4β2 nAChRs. Thus, at 10 µM 48, which totally inhibited α7 currents, 68 % 
inhibition was observed in α3β4 as well as in α4β2 nAChRs (not shown). 
Therefore, it appears that the N-benzylpiperidine moiety of these compounds is 
critical for their inhibitory activity, and that additional components such as the voluminous 
pyridinepropargylamine, 5-O-alkylindolomethylamine and indoloallylamine or much smaller 
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as ethylamine, present in compounds 13, 26, 38 and 48, respectively, contribute to enhance 
the inhibitory activity. 
Inhibition of cytosolic Ca2+ signals in a neuroblastoma cell line by compounds 13 and 
48. To explore the action of these compounds in a different context, we examined their effect 
on the cytosolic Ca
2+
 signals ([Ca
2+
]c) elicited by application of 200 µM ACh in SH-SY5Y 
neuroblastoma cells that express α7 and α3* nAChRs. 
31
 Compound 13 was chosen because 
it showed the largest potency in previous experiments, whereas compound 48, although 
having about the half of potency, also contained the N-benzylpiperidine motif but with much 
reduced molecular complexity. Figure 10A shows representative experiments carried out in 
SH-SY5Y cells in the absence (left panel) and in the presence of increasing concentrations of 
compounds 13 (central panel) and 48 (right panel). Application of only ACh elicited a sharp 
increase in [Ca
2+
]c that reached a plateau and then tended to slowly decline along the 50 s of 
the recording (left panel). A significant portion of this cholinergic signal seems to be 
mediated by α7 nAChRs, since it was increased about 2-fold in the presence of the specific 
α7 allosteric potentiator PNU120598
32
 (left panel). Preincubation of the cells with different 
concentrations of compounds 13 (center panel) and 48 (left panel) for 10 min induced a 
concentration-dependent decrease of the ACh-induced [Ca
2+
]c increase. Figure 10B shows 
concentration-response curves obtained by using this type of protocol in cells from three 
different cell cultures and five different concentrations of the compounds (0.3, 1, 3, 10, and 
30 µM). At the maximal concentrations of both compounds used, a 20% of the [Ca
2+
]c signal 
remained unblocked, probably reflecting their lower effect on the non-α7 nAChRs, which are 
present in these cells.
31
 The IC50 was calculated as 3.7 µM for compound 13 and 1.7 µM for 
compound 48. Thus, in this experimental setting, compound 48 was about two-fold more 
potent than compound 13.  
Page 8 of 31
ACS Paragon Plus Environment
ACS Chemical Neuroscience
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Action on other ligand-gated ion channels. Finally, we explored the effect of 
representative compounds (DNP, ASS234, 13, 26, 38 and 48) on glycine- and serotonin-
activated receptors expressed in Xenopus oocytes.  
At a 10 µM concentration no effect of any of these compounds was observed on 
homomeric α1 glycine receptors activated by 100 µM glycine (not shown). However, and 
except DNP, all of them inhibited 5-HT3A serotonin receptors at different extent (Figure 
11A). The most potent compounds were 38 and 13 (91 and 84 % inhibition, respectively), 
followed by 26, ASS234 (which showed a similar inhibition on α3β4 nAChRs, see Figure 2) 
and 48. Compounds 13 and 38 were selected for a more detailed study of concentration-
response relationships (Figure 11B). Compound 13 was the most potent inhibitor (IC50 1.4 
µM). This potency is intermediate between the observed with α7 nAChRs (0.32 µM) and the 
ones for α4β2 (6 µM) and α3β4 nAChRs (7.2 µM). Similarly, compound 38 was about 4-
fold less potent with 5-HT3A receptors (IC50 2.1 µM) than with α7 nAChRs (IC50 0.56 µM). 
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CONCLUSION 
In this study we have investigated the effect of different MTDPs on the function of nAChRs. 
We have found that MTDPs inhibit the peak current of nAChRs without modifying the 
macroscopic kinetics of the currents. The blocking effect of MTDPs on nAChRs is reversible 
and seems to be non-competitive. All the MTDPs analyzed in detail (ASS234 and compounds 
13, 26 and 38) appears to be highly selective for α7 nAChRs, although they can also inhibit 
to a lesser extent α3β4 and α4β2 nAChRs, as well as 5-HT3A serotonin receptors. These 
compounds have been considered potentially interesting for the treatment of AD, because 
their inhibitory actions on cholinesterase and monoamine oxidase enzymes.
11, 19, 21, 22
 
However, they might have a negative influence in this treatment, if we consider that 
activation, instead of inhibition, of neuronal nAChRs, and especially of the α7 subtype, is 
actually explored as a possibility of therapeutic intervention in AD.
33
 Nevertheless, the 
mechanism of action of α7 nAChRs on AD appears to be very complex,
34
 since both 
neuroprotection
35
 and neurotoxicity
36
 may be influenced by α7 nAChR activity. And, given 
the multifactorial nature of AD, the same might happen at the level of compounds used at 
present in its treatment. Thus, the frequently used galantamine and donepezil are both 
cholinesterase inhibitors, but the former can also act as positive allosteric modulator of 
neuronal nAChRs,
37
 whereas we have shown that donepezil behaves as a weak negative 
allosteric modulator (Figure 5). Also, compound ASS234 behaves as a cholinesterase 
inhibitor
14
 as well as a noncompetitive antagonist of neuronal nAChRs (Figure 2) but, in 
addition, inhibits Aβ aggregation and protects from Aβ-induced apoptosis in vitro,
15 
affecting 
in this way different processes involved in AD pathogenesis. Therefore, it is evident that the 
evaluation of a compound for its use in AD treatment must take into account many and rather 
diverse parameters.  
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All the studied donepezil derivatives bear in common the N-benzylpiperidine structural motif. 
Recently, α7 antagonists containing this motif have been described (the so-called compounds 
7, 7i and 8),
17
 although they differ at the rest of the molecule and are about 10-20-fold less 
potent acting on human α7 nAChRs expressed in Xenopus oocytes, thus confirming the 
importance of the non-piperidine component on the antagonistic properties. In fact, our study 
of less bulky derivatives showed that the ethylamine one (compound 48) was as potent as the 
larger ones (Figures 7-10). To our knowledge no other biological activity has been described 
for this molecule, which is only mentioned in a virtual search for trypanothione reductase 
inhibitors but with no positive result.
38
 Therefore, compound 48 could be a good starting 
point for further development of either positive or negative allosteric modulators of α7 
nAChRs with therapeutic potential in AD as well as in others diseases in which inhibition of 
this receptor subtype might play an important role. 
39
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EXPERIMENTAL SECTION 
Synthesis. All compounds described here have been prepared as indicated in the 
corresponding references. 
7-(3-(1-Benzylpiperidin-4-yl)propoxy)-3-phenyl-2H-chromen-2-one ASS352 (9). 
To a solution of 7-hydroxy-3-phenyl-2H-chromen-2-one
40
 (0.1 g, 0.42 mmol) and 1-benzyl-
4-(3-chloropropyl)piperidine
14 
(0.106 g, 0.42 mmol) in DMF (2 mL), NaH (16.8 mg, 1.73 
mmol, 60% /mineral) was added. The reaction mixture was stirred at room temperature 
overnight. After complete reaction (tlc analysis), the reaction was concentrated, diluted with 
water, and extracted with CH2Cl2. The organic phase was washed with brine, dried (MgSO4), 
and evaporated at reduced pressure. The crude product was purified by flash chromatography 
(CH2Cl2/AcOEt, 10:1 to 5/1, v/v) to give compound ASS352. (181.4 mg,  95%) as a white 
solid: Rf = 0.3 (hexane/EtOAc, 1/1); amorphousn solis; IR (KBr) ν 3430, 2936, 2920, 1708, 
1621, 1605, 1336, 1272, 1180, 1125 cm
-1
; 
1
H NMR (500 MHz, CDCl3) δ 7.76 (s, CH-4), 
7.71-7.67 (m, 2CH), 7.46-7.36 (m, 4H, Ph), 7.34-7.28 (m, 4H, Ph), 7.28-7.21 (CH, Ph), 6.86-
6.83 (m, 2CH, CH-6+CH-8), 4.02 (t, J= 6.5 Hz, 2H, -CH2-O-), 3.51 (s, 2H, PhCH2), 2.90 (d, 
J= 10.6 Hz, 1H, CH2, piperidine), 1.96 (t, J= 9.7 Hz, 2H, CH2, piperidine), 1.87-1.79 [m, 2H, 
-CH2-(CH2O)], 1.70 (d, J= 9.1 Hz, 2H, CH2, piperidine), 1.43-1.40 [m, 2H, -CH2-(CH2)2O-], 
1.31 (bs, 3H, CH+CH2, piperidine); 
13
C NMR (125 MHz, CDCl3) δ 162.1 (C7), 160.9 (C2), 
155.3 (C8a), 140.0 (CH-4), 138.5 (C, Ph), 135.0 (C, Ph), 129.2 (2CH, Ph), 128.7 (C5), 128.4 
(2CH, Ph), 128.3 (2CH, Ph), 128.1 (2CH, Ph), 126.9 (CH, Ph), 113.1 (C6), 113.2 (C4a), 
100.8 (C8), 68.8 (CH2O), 63.4 (PhCH2), 53.8 (2CH2, piperidine), 35.6 (CH, piperidine), 32.8 
[-CH2-(CH2)2O], 32.3 (2CH2, piperidine), 26.3 [-CH2-CH2O]; MS (EI) m/z (%): 454.57 
[M+H]
+
, 476.56 [M+Na]
+
. HRMS: Calculated for C30H31NO3 454.2377 [M+H]
+
. Found 
454.2363. Anal. Calcd. for C30H31NO3: C, 79.44; H, 6.89; N, 3.09. Found: C, 79.67; H, 6.78; 
N, 3.22. 
Oocyte expression. All cDNAs were cloned in derivatives of the pSP64T vector
41
 
containing part of the pBluescript polylinker. Capped mRNA was synthesized in vitro using 
SP6 RNA polymerase, the mMESSAGE-mMACHINE kit (ThermoFisher, Madrid, Spain) 
and the same pSP64T derivatives mentioned above. Defoliculated Xenopus laevis oocytes 
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were injected with 5 ng of each subunit cRNA in 50 nL of sterile water. All experiments were 
performed within 2-3 days after cRNA injection. 
Electrophysiological recordings. Two electrode voltage-clamp electrophysiological 
recordings in Xenopus oocytes were carried out as previously described.
42
 The extracellular 
solution contained (in mM): NaCl 82.5, KCl 2.5, BaCl2 2.5, MgCl2 1.0 and HEPES 5 (pH 
7.4) The replacement of calcium by barium in this solution diminishes the activation of 
calcium-activated chloride currents. The velocity of application of agonists through a tube 
located very close to the oocyte was 18-22 mL/min. The solution exchange rate followed an 
exponential time course with a time constant of 90 ms.
43
 Unless otherwise specified, 
compounds were pre-applied in the bath for 2 minutes and then co-applied with ACh through 
a pipette held very close to the oocyte for fast application and functional responses were 
estimated as the peak ionic current evoked by 4 s application of 200 µM ACh at -80 mV. All 
experiments were performed at 22ºC. Current records were measured with Clampfit 10.0 
(MDS Analytical Technologies, Sunnyvale, CA, USA).  
Data analysis. Normalized peak currents were obtained by dividing the maximum 
value of the current obtained in the presence of the compound by the maximum value of the 
current obtained in control conditions. Dose-response curves for the peak current obtained 
with ACh were fitted to the Hill equation:  
Normalized current = Imax / (1 + (EC50 / [ACh])
nH
), and dose-response inhibition curves were 
fitted to the modified Hill equation:  
Normalized current = 1 / (1+ ([compound] / IC50)
nH
). 
Data are expressed as mean ± SEM.  
SH-SY5Y cell culture. SH-SY5Y neuroblastoma cells were maintained in 
DMEM/Ham’s F-12 (1:1) media supplemented with 10% foetal calf serum, 2 mM glutamine, 
50 U/mL penicillin, and 50 µg/mL streptomycin (all products were purchased from Sigma, 
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Madrid, Spain), and were split every 3-4 d. For measurements of [Ca
2+
]c, cells were plated at 
a density of 2x10
5
 cells per well into 96-well plates. Cells were kept for 2 days at 37
o
C in a 
water-saturated incubator, with a 5% CO2/95% air atmosphere. Experiments were performed 
at room temperature (24+2
o
C). 
Measurement of [Ca
2+
]c. Cells were loaded with Krebs-HEPES (in mM: 144 NaCl, 
5.9 KCl, 1.2 MgCl2, 2 CaCl2, 11 D-glucose, 10 HEPES, pH 7.4) containing 10 µM fluo-4 
AM for 45 min at 37
o
C in the dark. After this incubation period, cells were washed twice 
with Krebs-HEPES at room temperature in the dark. Changes in fluorescence (excitation 485 
nm, emission 520 nm) were measured using a fluorescent plate reader (Fluostar, BMG 
Labtechnologies). Basal levels of fluorescence were monitored before adding stimulation 
solution (200 µM ACh) by using an automatic dispenser. After stimulation, changes in 
fluorescence were measured for 50 seg. To normalize fluo-4 signals, responses from each 
well were calibrated by measuring maximum and minimum fluorescence values. At the end 
of each experiment, addition of 5% Triton X-100 (Fmax) was followed by addition of 1 M 
MnCl2 (Fmin). Data were calculated as a percentage of Fmax - Fmin. 
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SUPPORTING INFORMATION  
Chemical structure of additional compounds is available free of charge via the Internet at 
http://pubs.acs.org. 
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ACh, acetylcholine; AD, Alzheimer’s disease; DNP, donepezil; MTDP, propargylamine; 
nAChRs, neuronal nicotinic acetylcholine receptors. 
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 FIGURES 
 
 
 
Figure 1.  Structure of compounds ASS234 and PF9601N (1). IC50 values of ASS234 for the 
inhibition of cholinesterase and monoamine oxidase enzymes are also indicated. 
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Figure 2. A) Representative ionic currents recorded in oocytes expressing human α7 
nAChRs. Currents were evoked by 600 ms applications of ACh 200 µM in the absence (first 
trace) and in the presence (remaining traces) of 1, 3 and 10 µM of ASS234. All currents were 
recorded at a holding potential of -80 mV. B) Concentration-response relationship for the 
inhibiting effect of ASS234 co-applied with ACh 200 µM. Continuous lines represent the fit 
to the Hill equation resulting in values of IC50 2.2 ± 0.4 µM and nH 1.6 ± 0.4. C) ACh 
concentration-response relationship in the absence (circles) and in the presence (triangles) of 
3 µM of ASS234, a concentration that was chosen because it is close to the IC50 value. All 
data were normalized to the response obtained by ACh 1 mM in control conditions. 
Continuous lines represent fits to Hill equations with the following parameters (Imax, EC50 in 
µM, nH) for ACh (1.22 ± 0.05, 207 ± 22, 1.3 ± 0.2) and ACh plus ASS234 (0.38 ± 0.05, 472 
± 130, 1.5 ± 0.4). D) Normalized current of α7, α3β4 and α4β2 receptors elicited by ACh in 
the presence of 10 µM of ASS234. Control values of peak inward currents (in µA) were: α7, 
1.32 ± 0.08; α4β2, 5.25 ± 0.42; α3β4, 11.62 ± 0.62. 
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Figure 3. Normalized current of α7 nAChRs elicited by 200 µM ACh in the presence of 10 
µM of compounds 1-41. Control values of peak inward currents for α7 nAChRs were 1.22 ± 
0.07 µA. 
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 22
 13,
 22
 22, 
21
 26,
21
 37-39.
19 
 
Page 24 of 31
ACS Paragon Plus Environment
ACS Chemical Neuroscience
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
-2 -1 0 1 2
0.0
0.5
1.0
DNP
13
26
38
Log [compound] (µM)
N
o
rm
a
li
z
e
d
 c
u
rr
e
n
t
0 1 2 3 4
0.0
0.5
1.0
Control
DNP
13
26
38
Log [ACh] (µM)
N
o
rm
a
liz
e
d
 c
u
rr
e
n
t
A
B
 
Figure 5. A) Dose-response curves of the inhibitory effect of compounds 13, 26, 38 and DNP 
on peak currents elicited by  ACh 200 µM in α7 nAChRs. Curves are fits to the modified Hill 
equation with the following parameters (IC50 in µM, nH): 13 (0.32 ± 0.02, 1.6 ± 0.2), 26 
(0.58 ± 0.05, 1.6 ± 0.2), 38 (0.56 ± 0.08, 1.2 ± 0.2) and DNP (10.2 ± 1.1, 1.3 ± 0.2). B) Dose-
response curves of peak current elicited by ACh in control conditions or ACh in the presence 
of 0.3 µM 13, 0.6 µM 26, 0.6 µM 38 or 10 µM DNP. Data have been normalized to the peak 
current obtained in control conditions with 1 mM ACh. Lines are fits to the Hill equation 
with parameters (Imax, EC50 in µM, nH):  control (1.2 ± 0.03, 202 ± 18.6, 1.4 ± 0.1), with 13 
(0.69 ± 0.05, 424 ± 94.5, 1.2 ± 0.3), with 26 (0.84 ± 0.14, 676 ± 285, 1.2 ± 0.5), with 38 (0.7 
± 0.1, 360 ± 157, 1.1 ± 0.4) and with DNP (0.88 ± 0.08, 563 ± 148, 1 ± 0.2). 
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Figure 6. A) Normalized current of α3β4 and α4β2 nAChRs elicited 200 µM ACh in the 
presence of 10 µM of compounds 13, 26, 38 and DNP. Control values of peak inward 
currents (in µA) were: α4β2, 5.18 ± 0.29; α3β4, 10.57 ± 0.40. B) Dose-response curves of 
the inhibitory effect of 13 on peak currents elicited by 200 µM ACh in α3β4 and α4β2 
nAChRs . Curves are fits to the modified Hill equation with the following parameters (IC50 in 
µM, nH): α3β4 (7.2 ± 1, 0.96 ± 0.1) and α4β2 (6 ± 0.9, 0.7 ± 0.1). 
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 Figure 7. N-Benzylpiperidine derivatives 42-50. 
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Figure 8. Normalized current of α7 nAChRs elicited by 200 µM ACh in the presence of 1 
and 10 µM of the indicated compounds. Control values of peak inward currents for 
α7 nAChRs were 1.36 ± 0.1 µA. 
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Figure 9. A) Dose-response curves of the inhibitory effect of compounds 47-50 on peak 
currents elicited by ACh 200 µM in α7 nAChRs. Curves are fits to the modified Hill equation 
with the following parameters (IC50 in µM, nH): 47 (2.2 ± 0.1, 1.5 ± 0.1), 48 (0.58 ± 0.07, 1 ± 
0.1), 49 (1.4 ± 0.4, 0.6 ± 0.1) and 50 (1 ± 0.2, 0.7 ± 0.1). B) Dose-response curves of peak 
current elicited by ACh in control conditions or ACh in the presence of 2 µM 47, 0.6 µM 48, 
2 µM 49 or 1 µM 50. Data have been normalized to the peak current obtained in control 
conditions with 1 mM ACh. Lines are fits to the Hill equation with parameters (Imax, EC50 in 
µM, nH):  control (1.22 ± 0.04, 207 ± 22.3, 1.3 ± 0.2), with 47 (0.79 ± 0.09, 458 ± 141, 1.1 ± 
0.2), with 48 (0.79 ± 0.04, 312 ± 35, 1.9 ± 0.4), with 49 (0.59 ± 0.06, 369 ± 101, 1.2 ± 0.2) 
and with 50 (0.89 ± 0.05, 277 ± 45, 1.3 ± 0.2). 
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 Figure 10. Effects of compounds 13 and 48 on [Ca
2+
]c in SH-SY5Y neuroblastoma cells. A) 
Representative recordings of the increase of [Ca
2+
]c induced by the application of 200 µM 
ACh in the absence and presence of 10 µM PNU120596 (left panel) and the blocking effects 
of compounds 13 (center panel) and 48 (right panel). Data are represented as % of Fmax-
Fmin. B) Normalized concentration-response curves of the inhibitory effects of compounds 
13 and 48 on ACh-induced [Ca
2+
]c changes. Data have been normalized with respect to the 
maximal response to ACh plus PNU120596 in the absence of drugs (% Fmax). 
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Figure 11. Effects of representative compounds on 5-HT3A receptors. A) Normalized current 
of 5-HT3A receptors elicited by 3 µM serotonin in the presence of 10 µM of the indicated 
compounds. B) Dose-response curves of the inhibitory effect of compounds 13 and 38 on 
peak currents elicited by serotonin in 5-HT3A receptors. Curves are fits to the modified Hill 
equation with the following parameters (IC50 in µM, nH): 13 (1.4 ± 0.4, 0.9 ± 0.2), 38 (2.1 ± 
0.3, 1.3 ± 0.2). 
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